Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial symbols : Mrk save search
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
Published: 2024-04-04 (Crawled : 12:00) - biospace.com/
MRK | $125.23 -0.11% 0.0% 6M
|
Health Technology
|
| O: 0.24%
H: 0.08%
C: -2.42%
mk-1084 keytruda lung merck cancer cell treatment trial
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
Published: 2024-04-03 (Crawled : 13:00) - biospace.com/
MRK | $125.23 -0.11% 0.0% 6M
|
Health Technology
|
| O: 0.13%
H: 0.0%
C: 0.0%
cancer trial initiated
Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer
Published: 2024-03-21 (Crawled : 12:00) - biospace.com/
MRK | $125.23 -0.11% 0.0% 6M
|
Health Technology
|
| O: -0.13%
H: 0.4%
C: -0.06%
ylynk-006 keytruda lung merck update cancer cell trial plus
Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9
Published: 2024-03-13 (Crawled : 11:00) - biospace.com/
MRK | $125.23 -0.11% 0.0% 6M
|
Health Technology
|
| O: 0.41%
H: 0.04%
C: -0.81%
gardasil vaccine merck trials
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced Urothelial Carcinoma After Surgery
Published: 2024-01-26 (Crawled : 23:00) - biospace.com/
MRK | $125.23 -0.11% 0.0% 6M
|
Health Technology
|
| O: 0.32%
H: 0.42%
C: 0.26%
keytruda advanced therapy
Merck Announces Phase 3 Trial Initiations for Four Investigational Candidates From its Promising Hematology and Oncology Pipeline
Published: 2024-01-05 (Crawled : 22:00) - biospace.com/
MRK | $125.23 -0.11% 0.0% 6M
|
Health Technology
|
| O: 0.08%
H: 0.29%
C: 0.1%
merck pipeline trial
Merck Announces KEYLYNK-008 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LYNPARZA® (olaparib) for Patients With Metastatic Squamous Non-Small Cell Lung Cancer to Stop for Futility
Published: 2023-12-07 (Crawled : 18:00) - biospace.com/
MRK | $125.23 -0.11% 0.0% 6M
|
Health Technology
|
| O: -0.04%
H: 0.01%
C: -1.61%
ylynk-008 keytruda lung merck cancer cell trial plus
Merck’s KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy Significantly Improved Progression-Free Survival (PFS) Versus Concurrent Chemoradiotherapy Alone in Newly Diagnosed, High-Risk Locally Advanced Cervical Cancer
Published: 2023-10-20 (Crawled : 19:00) - biospace.com/
MRK | $125.23 -0.11% 0.0% 6M
|
Health Technology
|
| O: -0.44%
H: 3.37%
C: 2.68%
keytruda cancer plus
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Statistically Significant Improvement in Pathological Complete Response (pCR) Rate
Published: 2023-10-20 (Crawled : 14:30) - biospace.com/
MRK | $125.23 -0.11% 0.0% 6M
|
Health Technology
|
| O: -0.44%
H: 3.37%
C: 2.68%
keytruda response plus
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by 28% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC)
Published: 2023-10-20 (Crawled : 14:30) - biospace.com/
MRK | $125.23 -0.11% 0.0% 6M
|
Health Technology
|
| O: -0.44%
H: 3.37%
C: 2.68%
keytruda lung cancer cell risk plus
KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Progression-Free Survival (PFS) Versus Trastuzumab
Published: 2023-10-20 (Crawled : 14:30) - biospace.com/
MRK | $125.23 -0.11% 0.0% 6M
|
Health Technology
|
| O: -0.44%
H: 3.37%
C: 2.68%
keytruda plus
Merck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of Overall Survival (OS) in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC)
Published: 2023-10-10 (Crawled : 12:00) - biospace.com/
MRK | $125.23 -0.11% 0.0% 6M
|
Health Technology
|
| O: -0.17%
H: 0.13%
C: -0.68%
ynote-671 lung merck cancer cell trial
Merck’s KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Muscle-Invasive Urothelial Carcinoma (MIUC) After Surgery
Published: 2023-10-05 (Crawled : 19:00) - biospace.com/
MRK | $125.23 -0.11% 0.0% 6M
|
Health Technology
|
| O: 0.19%
H: 1.32%
C: 1.21%
keytruda
Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer
Published: 2023-09-22 (Crawled : 12:00) - biospace.com/
MRK | $125.23 -0.11% 0.0% 6M
|
Health Technology
|
| O: 0.46%
H: 0.0%
C: -0.82%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -2.93%
H: 1.22%
C: 0.32%
keytruda lung merck update cancer cell trials plus
Merck Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
Published: 2023-09-22 (Crawled : 11:00) - biospace.com/
MRK | $125.23 -0.11% 0.0% 6M
|
Health Technology
|
| O: 0.46%
H: 0.0%
C: -0.82%
ev-302 merck cancer trial
Merck Initiates Phase 3 Clinical Program for Oral PCSK9 Inhibitor Candidate MK-0616
Published: 2023-08-25 (Crawled : 12:00) - biospace.com/
MRK | $125.23 -0.11% 0.0% 6M
|
Health Technology
|
| O: 0.45%
H: 0.35%
C: 0.25%
mk-0616 candidate merck program
Merck and Eisai Provide Update on Phase 3 LEAP-010 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Published: 2023-08-25 (Crawled : 12:00) - biospace.com/
MRK | $125.23 -0.11% 0.0% 6M
|
Health Technology
|
| O: 0.45%
H: 0.35%
C: 0.25%
leap-010 keytruda merck update cell trial plus
Merck Announces WELIREG® (belzutifan) Phase 3 LITESPARK-005 Trial Met Primary Endpoint of Progression-Free Survival in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
Published: 2023-08-18 (Crawled : 12:00) - biospace.com/
MRK | $125.23 -0.11% 0.0% 6M
|
Health Technology
|
| O: 0.05%
H: 0.49%
C: 0.21%
spark-005 welireg renal merck cell trial
Anixa Biosciences Announces Opening of Enrollment for Keytruda® Arm in Ongoing Breast Cancer Vaccine Clinical Trial
Published: 2023-08-07 (Crawled : 14:00) - biospace.com/
MRK | $125.23 -0.11% 0.0% 6M
|
Health Technology
|
| O: 0.28%
H: 0.94%
C: 0.76%
ANIX | News | $3.09 1.31% 1.29% 59K
|
Health Technology
|
| O: 0.0%
H: 2.66%
C: -4.27%
keytruda arm vaccine breast cancer ongoing trial
Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer
Published: 2023-07-28 (Crawled : 12:00) - biospace.com/
MRK | $125.23 -0.11% 0.0% 6M
|
Health Technology
|
| O: 0.15%
H: 1.16%
C: 0.86%
ynote-756 breast merck cancer trial response
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.